STOCK TITAN

Lantern Pharma Inc - LTRN STOCK NEWS

Welcome to our dedicated news page for Lantern Pharma (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lantern Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lantern Pharma's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.94%
Tags
AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
conferences
Lantern Pharma Inc

Nasdaq:LTRN

LTRN Rankings

LTRN Stock Data

105.05M
7.86M
15.06%
22.56%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Dallas

About LTRN

lantern pharma is leading a wave of innovation in cancer treatment that we believe will bring the best therapies to patients who are most likely to respond. we are pioneering precision medicine approach to cancer by tailoring promising drug programs to the right patients. our approach is to use biomarker based genetic screening to identify and treat patients that would benefit most from our drugs. we believe this approach will reduce the cost of development and increase the speed to market. our strategy is to acquire or partner with promising drug and diagnostic companies to move forward promising personalized medicine programs for cancer patients.